Design of anticancer prodrugs for reductive activation

Medicinal Research Reviews

Volumn 29, Issue 1, 2009, Pages 29-64

  Chen, Yu ^a   Hu, Longqin ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Bioreductive activation; Gene directed enzyme prodrug therapy (GDEPT); Hypoxia; Metal complex; N oxide; Nitroaromatic; Nitroreduction; Prodrug; Quinone; Target specific activation

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 1,4 NAPHTHOQUINONE DERIVATIVE; 4 [BIS(2 CHLOROETHYL)AMINO]BENZOIC ACID; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ACETYLSALICYLIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; APAZIQUONE; AROMATIC NITRO COMPOUND; BENZIMIDAZOLEQUINONE; BENZOQUINONE; BENZOQUINONE DERIVATIVE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; DIAZIQUONE; FLOXURIDINE; INDOLE DERIVATIVE; METAL COMPLEX; MISONIDAZOLE; MITOMYCIN C; NAPHTHOQUINONE; NITROREDUCTASE; NSC 639862; OXIDE; PORFIROMYCIN; PR 104; PR 104 A; PR 104 H; PR 104 M; PRODRUG; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SB 23862; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ADULT; CANCER THERAPY; CASE REPORT; CLINICAL TRIAL; CYTOTOXICITY; DRUG DESIGN; DRUG RELEASE; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HYPOXIA; OXIDATION REDUCTION REACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CYCLIC N-OXIDES; DRUG DESIGN; HUMANS; HYDROCARBONS, AROMATIC; ORGANOMETALLIC COMPOUNDS; OXIDATION-REDUCTION; PRODRUGS; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58849153727     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20137     Document Type: Review

References (216)

1. Hu LQ. Prodrugs: Effective solutions for solubility permeability and targeting challenges. I Drugs 2004;7(8):736-742.
2. Tanabe K, Zhang Z, Ito T, Hatta H, Nishimoto SI. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments. Org Biomol Chem 2007;5(23):3745-3757.
3. Denny WA. The design of selectively-activated prodrugs for cancer chemotherapy. Curr Pharm Des 1996;2(3):281-294.
4. Papot S, Tranoy I, Tillequin F, Florent JC, Gesson JP. Design of selectively activated anticancer prodrugs: Elimination and cyclization strategies. Curr Med Chem Anti-Cancer Agents 2002;2(2):155-185.
5. Sherwood RF. Advanced drug delivery reviews: Enzyme prodrug therapy. Adv Drug Deliv Rev 1996;22(3):269-288.
6. Sinhababu AK, Thakker DR. Prodrugs of anticancer agents. Adv Drug Deliv Rev 1996;19(2):241-273.
7. Rauth AM, Melo T, Misra V. Bioreductive therapies: An overviewof drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 1998;42(4):755-762.
8. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001;36(7-8):577-595.
9. Huang PS, Oliff A. Drug-targeting strategies in cancer therapy. Curr Opin Genet Dev 2001;11(1):104-110.
10. Jaffar M, Williams KJ, Stratford IJ. Bioreductive and gene therapy approaches to hypoxic diseases. Adv Drug Deliv Rev 2001;53(2):217-228.
11. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001;7(11):3314-3324.
12. Denny WA. Nitroreductase-based GDEPT. Curr Pharm Des 2002;8(15):1349- 1361.
13. Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002;26(7):783-789.
14. Denny WA. Tumor-activated prodrugs - A new approach to cancer therapy. Cancer Invest 2004;22(4):604-619.
15. Mckeown SR, Ward C, Robson T. Gene-directed enzyme prodrug therapy: A current assessment. Curr Opin Mol Ther 2004;6(4):421-435.
16. Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharm Rev 2004;56(1):53-102.
17. Barak Y, Thorne SH, Ackerley DF, Lynch SV, Contag CH, Matin A. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. Mol Cancer Ther 2006;5(1):97-103.
18. McKeown SR, Cowent RL, Williams KJ. Bioreductive drugs: From concept to clinic. Clin Oncol 2007;19(6):427-442.
19. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspect Med 2007;28(1):4-41.
20. Denny WA, Wilson WR. The design of selectively-activated anti-cancer prodrugs for use in antibodydirected and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol 1998;50(4):387-394.
21. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58(7):1408- 1416.
22. Tannock IF. Conventional cancer therapy: Promise broken or promise delayed? Lancet 1998;351:9-16.
23. Brown JM, William WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4(6):437-447.
24. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379(6560):88-91.
25. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62(12):3387-3394.
26. Searle PF, Chen MJ, Hu LQ, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI. Nitroreductase: A prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 2004;31(11):811-816.
27. Denny WA, Wilson WR. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 1986;29(6):879-887.
28. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Biol Med 2000;29(3-4):246-253.
29. Asche C. Antitumour quinones. Mini-Rev Med Chem 2005;5(5):449-467.
30. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 1988;48(4):775-778.
31. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: Crosslinking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997;76(1-3):73-87.
32. Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: Cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Regul 1998;38:111-133.
33. Gutierrez PL. The metabolism of quinone-containing alkylating agents: Free radical production and measurement. Front Biosci 2000;5:D629-D638.
34. Beall HD, Winski SL. Mechanisms of action of quinone-containing alkylating agents I: NQO1-directed drug development. Front Sci Ser 2000;5:D639-D648.
35. Xing CG, Skibo EB. Sigmatropic reactions of the aziridinyl semiquinone species: Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones. Abs Papers Am Chem Soc 2000;220:U567-U567.
36. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the national cancer institute tumor cell line panel: Correlation with sensitivity to mitomycin C and E09. J Nat Cancer Inst 1996;88(5):259-269.
37. Robertson N, Haigh A, Adams GE, Stratford IJ. Factors affecting sensitivity to Eo9 in rodent and human tumor-cells in-vitro - Dt-diaphorase activity and hypoxia. Eur J Cancer 30(7):1013-1019.
38. Plumb JA, Gerritsen M, Workman P. Dt-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 1994;70(6):1136-1143.
39. Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P. Relative importance of Dt-diaphorase and hypoxia in the bioactivation of Eo9 by human lung-tumor cell-lines. Int J Radiat Oncol Biol Phys 1994; 29(2):295-299.
40. Workman P. Enzyme-directed bioreductive drug development revisited - A commentary on recent progress and future-prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly Dt-diaphorase. Oncol Res 1994;6(10-11):461-475.
41. Igarashi Y, Oki T. Mannose-binding quinone glycoside, MBQ: Potential utility and action mechanism. Adv Appl Microbiol 2004;54:147-166.
42. van der Heijden AG, Moonen PMJ, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: Toxicity and marker response. J Urol 2006;176(4):1349-1353.
43. Phillips RM, Loadman PM, Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 1998;77(12):2112-2119.
44. Naylor MA, Jaffar M, Nolan J, Stephens MA, Butler S, Patel KB, Everett SA, Adams GE, Stratford IJ. 2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: Structureactivity in vitro and efficacy in vivo. J Med Chem 1997;40(15):2335-2346.
45. Phillips RM, Naylor MA, Jaffar M, Doughty SW, Everett SA, Breen AG, Choudry GA, Stratford IJ. Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships. J Med Chem 1999;42(20):4071-4080.
46. Swann E, Barraja P, Oberlander AM, Gardipee WT, Hudnott AR, Beall HD, Moody CJ. Indolequinone antitumor agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H: Quinone oxidoreductase. Part 2. J Med Chem 2001;44(20):3311-3319.
47. Naylor MA, Swann E, Everett SA, Jaffar M, Nolan J, Robertson N, Lockyer SD, Patel KB, Dennis MF, Stratford MRL, Wardman P, Adams GE, Moody CJ, Stratford IJ. Indolequinone antitumor agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. J Med Chem 1998;41(15):2720-2731.
48. Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, Moody CJ. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H: Quinone oxidoreductase 1 (NQO1) activity. J Med Chem 2007;50(23):5780-5789.
49. Jaffar M, Phillips RM, Williams KJ, Mrema I, Cole C, Wind NS, Ward TH, Stratford IJ, Patterson AV. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: Mechanism of activation and cytotoxicity in vitro. Biochem Pharmacol 2003;66(7):1199-1206.
50. Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, Moody CJ. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: Quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem 1998;41(24):4755-4766.
51. Newsome JJ, Swann E, Hassani M, Bray KC, Slawin AMZ, Beall HD, Moody CJ. Indolequinone antitumour agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Org Biomol Chem 2007;5(10):1629-1640.
52. Gibson NW, Hartley JA, Butler J, Siegel D, Ross D. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol Pharmacol 1992;42(3):531-536.
53. Begleiter A, Leith MK, Patel D, Hasinoff BB. Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol 2007;60(5):713-723.
54. Hasinoff BB, Wu X, Begleiter A, Guziec LJ, Guziec F Jr, Giorgianni A, Yang S, Jiang Y, Yalowich JC. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol 2006;57(2):221-233.
55. Fourie J, Guziec F Jr, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A. Structure-activity study with bioreductive benzoquinone alkylating agents: Effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity. Cancer Chemother Pharmacol 2004;53(3):191-203.
56. Phillips RM, Jaffar M, Maitland DJ, Loadman PM, Shnyder SD, Steans G, Cooper PA, Race A, Patterson AV, Stratford IJ. Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Biochem Pharmacol 2004;68(11):2107-2116.
57. Skibo EB. The discovery of the pyrrolo[1,2-a]benzimidazole antitumor agents - The design of selective antitumor agents. Curr Med Chem 1996;3(1):47-78.
58. Skibo EB, Gordon S, Bess L, Boruah R, Heileman MJ. Studies of pyrrolo[1,2-a]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation. J Med Chem 1997;40(9):1327-1339.
59. Lynch M, Hehir S, Kavanagh P, Leech D, O'Shaughnessy J, Carty MP, Aldabbagh F. Synthesis by radical cyclization and cytotoxicity of highly potent bioreductive alicyclic ring fused [1,2-a]benzimidazolequinones. Chem Eur J 2007;13(11):3218-3226.
60. Fryatt T, Pettersson HI, Gardipee WT, Bray KC, Green SJ, Slawin AMZ, Beall HD, Moody CJ. Novel quinolinequinone antitumor agents: Structure-metabolism studies with NAD(P)H: Quinone oxidoreductase (NQO1). Bioorg Med Chem 2004;12(7):1667-1687.
61. Fryatt T, Goroski DT, Nilson ZD, Moody CJ, Beall HD. Novel quinolinequinone antitumor agents: Structure-metabolism studies with NAD(P)H: Quinone oxidoreductase (NQO1). Bioorg Med Chem Lett 1999;9(15):2195-2198.
62. Hernick M, Flader C, Borch RF. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. J Med Chem 2002;45(16):3540-3548.
63. Tanabe K, Makimura Y, Tachi Y, Imagawa-Sato A, Nishimoto S. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: Radiolytic reduction and cytotoxicity characteristics. Bioorg Med Chem Lett 2005;15(9):2321-2324.
64. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: Current perspectives. Bioorg Med Chem 2004;12(7):1585-1604.
65. Shamis M, Lode HN, Shabat D. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. J Am Chem Soc 2004;126(6):1726-1731.
66. Rahier NJ, Eisenhauer BM, Gao R, Jones SH, Hecht SM. Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons. Org Lett 2004;6(3):321-324.
67. Pessah N, Reznik M, Shamis M, Yantiri F, Xin H, Bowdish K, Shomron N, Ast G, Shabat D. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs. Bioorg Med Chem 2004;12(8):1859-1866.
68. Paranjpe PV, Chen Y, Kholodovych V, Welsh W, Stein S, Sinko PJ. Tumor-targeted bioconjugate based delivery of camptothecin: Design, synthesis and in vitro evaluation. J Controlled Release 2004;100(2):275-292.
69. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjugate Chem 2003;14(5):1007-1017.
70. Singer JW, Bhatt R, Tulinsky J, Buhler KR, Heasley E, Klein P, de Vries P. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Controlled Release 2001;74(1-3):243-247.
71. Zhang Z, Tanabe K, Hatta H, Nishimoto S. Bioreduction activated prodrugs of camptothecin: Molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity. Org Biomol Chem 2005;3(10):1905-1910.
72. Jaffar M, Naylor MA, Robertson N, Lockyer SD, Phillips RM, Everett SA, Adams GE, Stratford IJ. 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl- 1-methyl-2-[1H-indole-4,7-dione]prop-2-en-1-ol (E09, NSC 382459) and their regioisomers as hypoxia-selective agents: Structure-cytotoxicity in vitro. Anti-Cancer Drug Des 1998;13(2):105-123.
73. Faig M, Bianchet MA, Winski S, Hargreaves R, Moody CJ, Hudnott AR, Ross D, Amzel LM. Structure-based development of anticancer drugs: Complexes of NAD(P)H: Quinone oxidoreductase 1 with chemotherapeutic quinones. Structure 2001;9(8):659-667.
74. Jaffar M, Everett SA, Naylor MA, Moore SG, Ulhaq S, Patel KB, Stratford MRL, Nolan J, Wardman P, Stratford IJ. Prodrugs for targeting hypoxic tissues: Regiospecific elimination of aspirin from reduced indolequinones. Bioorg Med Chem Lett 1999;9(1):113-118.
75. Hernick M, Borch RF. Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs. J Med Chem 2003;46(1):148-154.
76. de Groot FMH, Damen EWP, Scheeren HW. Anticancer prodrugs for application in monotherapy: Targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem 2001;8(9):1093-1122.
77. Wang B, Nicolaou MG, Liu S, Borchardt RT. Structural analysis of a facile lactonization system facilitated by a "trimethyl lock". Bioorg Chem 1996;24(1):39-49.
78. Carpino LA, Triolo SA, Berglund RA. Reductive lactonization of strategically methylated quinone propionic acid esters and amides. J Org Chem 1989;54(14):3303-3310.
79. Wang W, Jiang J, Ballard CE, Wang B. Prodrug approaches to the improved delivery of peptide drugs. Curr Pharm Des 1999;5(4):265-287.
80. Testa B, Mayer JM. Design of intramolecularly activated prodrugs. Drug Metab Rev 1998;30(4):787-807.
81. Maskell L, Blanche EA, Colucci MA, Whatmore JL, Moody CJ. Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles. Bioorg Med Chem Lett 2007;17(6):1575-1578.
82. Volpato M, Abou-Zeid N, Tanner RW, Glassbrook LT, Taylor J, Stratford I, Loadman PM, Jaffar M, Phillips RM. Chemical synthesis and biological evaluation of a NAD(P)H: Quinone oxidoreductase-1-targeted tripartite quinone drug delivery system. Mol Cancer Ther 2007;6(12):3122-3130.
83. Flader C, Liu JW, Borch RF. Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. J Med Chem 2000;43(16):3157-3167.
84. Stratford IJ, O'Neill P, Sheldon PW, Silver AR, Walling JM, Adams GE. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 1986;35:5.
85. Stratford IJ, Adams GE, Godden J, Howells N. Induction of tumour hypoxia post-irradiation: A method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol 1989;55:12.
86. Binger M, Workman P. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2- nitro-1H-imidazole-1-ethanol (RSU 1069). Cancer Chemother Pharmacol 1991;29(1):37-47.
87. Naylor MA, Threadgill MD, Showalter HD, Stratford IJ, Stephens MA, Fielden EM, Adams GE. Synthesis of the enantiomers of the bioreductively- activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro. Drug Des Discov 1993;10(3):249-255.
88. Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 1998;26(2):234-239.
89. Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J Med Chem 1994;37(3):381-391.
90. Hay MP, Wilson WR, Denny WA. A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (adept) using Escherichia-Coli-B nitroreductase. Bioorg Med Chem Lett 1995;5(23):2829-2834.
91. Moselen JW, Hay MP, Denny WA, Wilson WR. N-[2-(2-Methyl-5- nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl) butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res 1995;55(3):574-580.
92. Anderson RF, Denny WA, Roberts PB, Wardman P, White J, Wilson WR. Correlation of the radiosensitization potency afforded by nitroacridine intercalators with their electron scavenging efficiency in DNA. Int J Radiat Oncol Biol Phys 1992;22(3):537-540.
93. Wilson WR, Thompson LH, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. J Med Chem 1989;32(1):31-38.
94. Stallings WC, Glusker JP, Carrell HL, Bogucka-Ledochowska M, Ledochowski A, Stezowski JJ. Intercalation model for DNA-cross linking in a 1-nitro-9-aminoacridine derivative, an analog of the antitumor agent "ledakrin" (nitracrine). J Biomol Struct Dyn 1984;2(3):511-524.
95. Buchko Garry W, Weinfeld M, DNA-targeted 2-nitroimidazoles: Studies of the influence of the phenanthridine-linked nitroimidazoles, 2-NLP-3 and 2-NLP-4, on DNA damage induced by ionizing radiation. Radiat Res 2002;158(3):302-310.
96. Cowan DS, Matejovic JF, McClelland RA, Rauth AM. DNA-targeted 2-nitroimidazoles: In vitro and in vivo studies. Br J Cancer 1994;70(6):1067-1074.
97. Denny WA, Roberts PB, Anderson RF, Brown JM, Phil D, Wilson WR. NLA-1: A 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int J Radiat Oncol Biol Phys 1992;22(3):553-556.
98. Cowan DS, Panicucci R, McClelland RA, Rauth AM. Targeting radiosensitizers to DNA by attachment of an intercalating group: Nitroimidazole-linked phenanthridines. Radiat Res 1991;127(1):81-89.
99. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-nitro-1-imidazolyl) propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 2000;12(4):185-192.
100. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNAintercalating bioreductive drug. Clin Cancer Res 2003;9(15):5714- 5720.
101. Wilson WR, Denny WA, Twigden SJ, Baguley BC, Probert JC. Selective toxicity of nitracrine to hypoxic mammalian cells. Br J Cancer 1984;49(2):215-223.
102. Wilson WR, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. J Med Chem 1989;32(1):23-30.
103. Wilson WR, Denny WA, Stewart GM, Fenn A, Probert JC. Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int J Radiat Oncol Biol Phys 1986;12(7):1235-1238.
104. Wilson WR, Siim BG, Denny WA, van Zijl PL, Taylor ML, Chambers DM, Roberts PB. 5-Nitro-4-(N,N-dimethylaminopropylamino) quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. Radiat Res 1992;131(3):257-265.
105. Cobb LM, Connors TA, Elson LA, Khan AH, Mitchley BCV, Ross WCJ, Whisson ME. A potent and selective inhibitor of growth of the walker carcinomo 256. Biochem Pharmacol 1969;18:9.
106. Knox RJ, Burke PJ, Chen S, Kerr DJ. CB1954: From the walker tumor to NQO2 and VDEPT. Curr Pharm Des 2003;9(26):2091-2104.
107. Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992;44(12):2297-2301.
108. Knox RJ, Friedlos F, Marchbank T, Roberts JJ. Bioactivation of CB 1954: Reaction of the active 4-hydroxylami derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol 1991;42(9):1691-1697.
109. Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 2004;90(5):1084-1092.
110. Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA, Wilson WR. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen Mustard SN 23862: Distinct mechanisms of bioreductiv activation. Chem Res Toxicol 2003;16(4):469-478.
111. Palmer BD, Wilson WR, Atwell GJ, Schultz D, Xu XZ, Denny WA. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl) amino]-2,4-dinitrobenzamide. J Med Chem 1994;37(14):2175-2184.
112. Palmer BD, Wilson WR, Anderson RF, Boyd M, Denny WA. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4- dinitrobenzamide. J Med Chem 1996;39(13):2518-2528.
113. Patterson AV, Ferry DM, Edmunds SJ, Gu YC, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang SJ, Denny WA, Wilson WR. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13(13):3922-3932.
114. Atwell GJ, Yang SJ, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. J Med Chem 2007;50(6):1197-1212.
115. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH: Cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007;74(6):810-820.
116. Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9(26):2131-2154.
117. Helsby NA, Atwell GJ, Yang SJ, Palmer BD, Anderson RF, Pullen SM, Ferry DM, Hogg A, Wilson WR, Denny WA. Aziridinyldinitrobenzamides: Synthesis and structure-activity relationships for activation by E-coli nitroreductase. J Med Chem 2004;47(12):3295-3307.
118. Tercel M, Wilson WR, Denny WA. Nitrobenzyl mustard quaternary salts: A new class of hypoxia-selective cytotoxins showing very high in vitro selectivity. J Med Chem 1993;36(17):2578-2579.
119. Tercel M, Wilson WR, Anderson RF, Denny WA. Hypoxia-selective antitumor agents 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 1996;39(5):1084-1094.
120. Tercel M, Lee AE, Hogg A, Anderson RF, Lee HH, Siim BG, Denny WA, Wilson WR. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 2001;44(21):3511-3522.
121. Firestone A, Mulcahy RT, Borch RF. Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J Med Chem 1991;34(9):2933-2935.
122. Mulcahy RT, Gipp JJ, Schmidt JP, Joswig C, Borch RF. Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating-agents. J Med Chem 1994;37(11):1610-1615.
123. Borch RF, Liu JW, Schmidt JP, Marakovits JT, Joswig C, Gipp JJ, Mulcahy RT. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. J Med Chem 2000;43(11):2258-2265.
124. Borch RF, Liu JW, Joswig C, Baggs RB, Dexter DL, Mangold GL. Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates. J Med Chem 2001;44(1):74-77.
125. Hu LQ, Yu CZ, Jiang YY, Han JY, Li ZR, Browne P, Race PR, Knox RJ, Searle PF, Hyde EI. Nitroaryl phosphoramides as novel prodrugs for E-coli nitroreductase activation in enzyme prodrug therapy. J Med Chem 2003;46(23):4818-4821.
126. Li ZR, Han JY, Jiang YY, Browne P, Knox RJ, Hu LQ. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: Synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Bioorg Med Chem 2003;11(19):4171-4178.
127. Jiang YY, Han JY, Yu CZ, Vass SO, Searle PF, Browne P, Knox RJ, Hu LQ. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E-coli nitroreductase activation. J Med Chem 2006;49(14):4333-4343.
128. Thomson P, Naylor MA, Everett SA, Stratford MRL, Lewis G, Hill S, Patel KB, Wardman P, Davis PD. Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4. Mol Cancer Ther 2006;5(11):2886-2894.
129. Thomson P, Naylor MA, Stratford MRL, Lewis G, Hill S, Patel KB, Wardman P, Davis PD. Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs. Bioorg Med Chem Lett 2007;17(15):4320-4322.
130. Carl PL, Charkravarty PK, Katzenellenbogen JA. A Novel connector linkage applicable in prodrug design. J Med Chem 1981;24(5):2.
131. Mauger AB, Burke PJ, Somani HH, Friedlos F, Knox RJ. Self-immolative prodrugs - Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem 1994;37(21):3452-3458.
132. Hay MP, Wilson WR, Denny WA. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase genedirected enzyme prodrug therapy (GDEPT). Bioorg Med Chem Lett 1999;9(24):3417-3422.
133. Asche C, Dumy P, Carrez D, Croisy A, Demeunynck M. Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy. Bioorg Med Chem Lett 2006;16(7):1990-1994.
134. Ouberai M, Asche C, Carrez D, Croisy A, Dumy P, Demeunynck M. 3,4-Dihydro-1H-[1,3]oxazino[4,5-c]acridines as a new family of cytotoxic drugs. Bioorg Med Chem Lett 2006;16(17):4641-4643.
135. Charmantray F, Demeunynck M, Carrez D, Croisy A, Lansiaux A, Bailly C, Colson P. 4-hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents. J Med Chem 2003;46(6):967-977.
136. Hay MP, Atwell GJ, Wilson WR, Pullen SM, Denny WA. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz e indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E-coli nitroreductase. J Med Chem 2003;46(12):2456-2466.
137. Hay MP, Wilson WR, Denny WA. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. Bioorg Med Chem 2005;13(12):4043-4055.
138. Hay MP, Sykes BM, Denny WA, Wilson WR. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1, 2-dihydro-3H-benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg Med Chem Lett 1999;9(15):2237-2242.
139. Hay MP, Wilson WR, Denny WA. Design, synthesis and evaluation of imidazolylmethyl carbamate prodrugs of alkylating agents. Tetrahedron 2000;56(4):645-657.
140. Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. J Med Chem 2003;46(25):5533-5545.
141. Duan J-X, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51(8):2412-2420.
142. Atwell GJ, Sykes BM, Oconnor CJ, Denny WA. Relationships between structure and kinetics of cyclization of 2-aminoaryl amides - Potential prodrugs of cyclization-activated aromatic mustards. J Med Chem 1994;37(3):371-380.
143. Liu B, Hu LQ. 5′-(2-Nitrophenylalkanoyl)-2′-deoxy-5- fluorouridines as potential prodrugs of FUDR for reductive activation. Bioorg Med Chem 2003;11(18):3889-3899.
144. Hu LQ, Liu B, Hacking DR. 5′-[2-(2-nitrophenyl)-2-methylpropionyl]- 2′-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: Synthesis, stability and reductive activation. Bioorg Med Chem Lett 2000;10(8):797-800.
145. Sykes BM, Atwell GJ, Hogg A, Wilson WR, O'Connor CJ, Denny WA. N-substituted 2-(2,6-dinitrophenylamino)propanamides: Novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. J Med Chem 1999;42(3):346-355.
146. Sugiura K. Antitumor activity of purine N-oxides and effect of selected compounds on tumors induced by purine N-oxides. Cancer Chemother Rep 2 1968;1(2):383-402.
147. Chen X, Jin Y. study of bioreductive drugs. J Radiat Res Radiat Process 2003;21(2):83-87.
148. Cerecetto H, Gonzalez M. N-oxides as hypoxia selective cytotoxins. Mini-Rev Med Chem 2001;1:219-231.
149. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12(7):1239-1242.
150. Patterson AV, Saunders MP, Chinje EC, Patterson LH, Stratford IJ. Enzymology of tirapazamine metabolism: A review. Anti-Cancer Drug Des 1998;13(6):541-573.
151. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993;53(17):3992-3997.
152. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000;18(6):1351-1359.
153. Daniels JS, Gates KS. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J Am Chem Soc 1996;118(14):3380-3385.
154. Shinde SS, Anderson RF, Hay MP, Gamage SA, Denny WA. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4- benzotriazine 1,4-dioxides. J Am Chem Soc 2004;126(25):7865-7874.
155. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. JAm Chem Soc 2003;125(3):748-756.
156. Anderson RF, Shinde SS, Hay MP, Denny WA. Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: The role of redox equilibria. JAm Chem Soc 2006;128(1):245-249.
157. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4- benzotriazine 1,4-dioxides. Org Biomol Chem 2005; 3(11):2167-2174.
158. Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, Shinde SS, Phillips V, Denny WA, Wilson WR. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: The influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem 2007;50(26):6654-6664.
159. Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 2003;46(1):169-182.
160. Kelson AB, McNamara JP, Pandey A, Ryan KJ, Dorie MJ, McAfee PA, Menke DR, Brown JM, Tracy M. 1,2,4-benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anti-Cancer Drug Des 1998;13(6):575-592.
161. Hay MP, Pruijn FB, Gamage SA, Liyanage HDS, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: Potent analogues of the hypoxia-selective cytotoxin tirapazamine. J Med Chem 2004;47(2):475-488.
162. Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem Pharmacol 2003;65(11):1807-1815.
163. Hicks KI, Pruijn FB, Secomb TW, Hay MR, Hsu R, Brown JM, Denny WA, Dewhirst MW, Wilson WR. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98(16):1118-1128.
164. Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA. Pharmacokinetic/ pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport. J Med Chem 2007;50(25):6392-6404.
165. Ganley B, Chowdhury G, Bhansali J, Daniels JS, Gates KS. Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide. Bioorg Med Chem 2001;9(9):2395-2401.
166. Priyadarsini KI, Dennis MF, Naylor MA, Stratford MRL, Wardman P. Free radical intermediates in the reduction of quinoxaline N-oxide antitumor drugs: Redox and prototropic reactions. J Am Chem Soc 1996;118(24):5648-5654.
167. Solano B, Junnotula V, Marin A, Villar R, Burguete A, Vicente E, Perez-Silanes S, Aldana I, Monge A, Dutta S, Sarkar U, Gates KS. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J Med Chem 2007;50(22):5485-5492.
168. Amin KM, Ismail MMF, Noaman E, Soliman DH, Ammar YA. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides. Bioorg Med Chem 2006;14(20):6917-6923.
169. Zarranz B, Jaso A, Aldana I, Monge A. Synthesis and anticancer activity evaluation of new2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. Bioorg Med Chem 2004;12(13):3711-3721.
170. Ortega MA, Morancho MJ, Martinez-Crespo FJ, Sainz Y, Montoya ME, de Cerain AL, Monge A. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents. Eur J Med Chem 2000;35(1):21-30.
171. Monge A, Palop JA, Decerain AL, Senador V, Martinezcrespo FJ, Sainz Y, Narro S, Garcia E, Demiguel C, Gonzalez M, Hamilton E, Barker AJ, Clarke ED, Greenhow DT. Hypoxia-selective agents derived from quinoxaline 1,4-Di-N-oxides. J Med Chem 1995;38(10):1786-1792.
172. Monge A, Martinez-Crespo FJ, Lopez de Cerain A, Palop JA, Narro S, Senador V, Marin A, Sainz Y, Gonzalez M, et al. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-Di-N-oxides. 2. J Med Chem 1995;38(22):4488-4494.
173. Naylor MA, Stephens MA, Nolan J, Sutton B, Tocher JH, Fielden EM, Adams GE, Stratford IJ. Heterocyclic mono-N-oxides with potential applications as bioreductive antitumor drugs. 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines. Anti-Cancer Drug Des 1993;8(6):439-461.
174. Langmuir VK, Laderoute KR, Mendonca HL, Sutherland RM, Hei TK, Liu SX, Hall EJ, Naylor MA, Adams GE. Fused pyrazine mono-n-oxides as bioreductive drugs. II Cytotoxicity in human cells and oncogenicity in a rodent transformation assay. Int J Radiat Oncol Biol Phys 1996;34(1):79-84.
175. Naylor MA, Adams GE, Haigh A, Cole S, Jenner T, Robertson N, Siemann D, Stephens MA, Stratford IJ. Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo. Anticancer Drugs 1995;6(2):259-269.
176. Barham HM, Stratford IJ. Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase. Biochem Pharmacol 1996;51(6):829-837.
177. Naylor MA, Sutton BM, Nolan J, O'Neill P, Fielden EM, Adams GE, Stratford IJ. Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity. Int J Radiat Oncol Biol Phys 1994;29(2):333-337.
178. Boiani M, Cerecetto H, Gonzalez M, Risso M, Olea-Azar C, Piro OE, Castellano EE, Lopez de Cerain A, Ezpeleta O, Monge-Vega A. 1,2,5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: Synthesis and biological evaluation. Part IV. Eur J Med Chem 2001;36(10):771-782.
179. Monge A, Lopez de Cerain A, Ezpeleta O, Cerecetto H, Dias E, Di Maio R, Gonzalez M, Onetto S, Seoane G, Suescun L, Mariezcurrena R. Synthesis and biological evaluation of 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins. Pharmazie 1998;53(11):758-764.
180. Monge A, Lopez De Cerain A, Ezpeleta O, Cerecetto H, Dias E, Di Maio R, Gonzalez M, Onetto S, Risso M, Seoane G, Zinola F, Olea-Azar C. 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins. Structure-activity relationships. Pharmazie 1998;53(10):698-702.
181. Cerecetto H, Gonzalez M, Risso M, Saenz P, Olea-Azar C, Bruno AM, Azqueta A, De Cerain AL, Monge A. 1,2,4-triazine N-oxide derivatives: Studies as potential hypoxic cytotoxins. Part III. Arch Pharm 2004;337(5):271-280.
182. Cerecetto H, Gonzalez M, Onetto S, Saenz P, Ezpeleta O, De Cerain AL, Monge A. 1,2,4-Triazine N-oxide derivatives: Studies as potential hypoxic cytotoxins. Part II. Arch Pharm 2004;337(5):247-258.
183. Cerecetto H, Gonzalez M, Onetto S, Risso M, Saenz P, Seoane G, Bruno AM, Alarcon J, Olea-Azar C, De Cerain AL, Ezpeleta O, Monge A. 1,2,4-Triazine N-oxide and N,N′-dioxide derivatives: Studies as potential hypoxic cytotoxins and DNA binder. Med Chem Res 2001;10(5):328-337.
184. Cerecetto H, Gonzalez M, Lavaggi ML, Aravena MA, Rigol C, Olea-Azar C, Azqueta A, Lopez de Cerain A, Monge A, Bruno AM. Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins: Part II. Structure-activity relationship studies. Med Chem 2006;2(5):511-521.
185. Cerecetto H, Gonzalez M, Lavaggi ML, Porcal W. Preparation of phenazine N5,N10-dioxides. Effects of benzofuroxan substituents in the outcome of their expansion reaction with phenolates. J Braz Chem Soc 2005;16(6A):1290-1296.
186. Cerecetto H, Gonzalez M, Lavaggi ML, Azqueta A, Lopez de Cerain A, Monge A. Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxinss. J Med Chem 2005;48(1):21-23.
187. Smith PJ, Blunt NJ, Desnoyers R, Giles Y, Patterson LH. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 1997;39(5):455-461.
188. Patterson LH. Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 2002;34(3):581-592.
189. McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 2005;7(7):851-859.
190. McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther 2003;10(1):40-48.
191. Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T. Tumor-selective drug activation: A GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther 2006;13(6):598-605.
192. Lee HH, Wilson WR, Ferry DM, vanZijl P, Pullen SM, Denny WA. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. J Med Chem 1996;39(13):2508-2517.
193. Yin H, Xu YF, Qian XH, Li YL, Liu HW. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: Synthesis and biological evaluation. Bioorg Med Chem Lett 2007;17(8):2166-2170.
194. White INH, Suzanger M, Mattocks AR, Bailey E, Farmer PB, Connors TA. Reduction of nitromin to nitrogen mustard: Unscheduled DNA synthesis in aerobic or anaerobic rat hepatocytes, JB1, BL8 and Walker carcinoma cell lines. Carcinogenesis 1989;10(11):2113-2118.
195. Tercel M, Wilson WR, Denny WA. Hypoxia-selective antitumor agents. 11. Chlorambucil N-oxide: A reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. J Med Chem 1995;38(7):1247-1252.
196. Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA, Patterson LH. Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. Mol Cancer Ther 2003;2(7):607-610.
197. Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor. J Med Chem 2004;47(7):1856-1859.
198. Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, Searcey M, Patterson LH. Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: Potential for development of tumor-selective N-oxides. J Med Chem 2006;49(24):7013-7023.
199. Highfield JA, Mehta LK, Parrick J, Candeias LP, Wardman P. Preparative, physico-chemical and cytotoxicity studies of prodrugs activated in hypoxia to give metal-binding analogues of bleomycin. J Chem Soc Perkin Trans 1 1999(16):2343-2351.
200. Blower PJ, Dilworth JR, Maurer RI, Mullen GD, Reynolds CA, Zheng YF. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J Inorg Biochem 2001;85(1):15-22.
201. Hall MD, Failes TW, Yamamoto N, Hambley TW. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. Dalton Trans 2007;(36):3983-3990.
202. Anderson RF, Denny WA, Ware DC, Wilson WR. Pulse radiolysis studies on the hypoxia-selective toxicity of a colbalt-mustard complex. Br J Cancer Suppl 1996;27:S48-S51.
203. Hambley TW. Developing new metal-based therapeutics: Challenges and opportunities. Dalton Trans 2007;(43):4929-4937.
204. Ware DC, Palmer HR, Pruijn FB, Anderson RE, Brothers PJ, Denny WA, Wilson WR. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: Synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. Anti-Cancer Drug Des 1998;13(2):81-103.
205. Wilson WR, Moselen JW, Cliffe S, Denny WA, Ware DC. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: The cobalt(III)-nitrogen mustard complex SN 24771. Int J Radiat Oncol Biol Phys 1994;29(2):323-327.
206. Ware DC, Palmer BD, Wilson WR, Denny WA. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a newclass of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem 1993;36(13):1839-1846.
207. Parker LL, Lacy SM, Farrugia LJ, Evans C, Robins DJ, O'Hare CC, Hartley JA, Jaffar M, Stratford IJ. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J Med Chem 2004;47(23):5683-5689.
208. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001;19(15): 3447-3455.
209. Failes TW, Cullinane C, Diakos CI, Yamamoto N, Lyons JG, Hambley TW. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: A potential hypoxia-activated prodrug. Chem Eur J 2007; 13(10):2974-2982.
210. Failes TW, Hambley TW. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat. J Inorg Biochem 2007;101(3):396-403.
211. Failes TW, Diakos CI, Underwood CK, Hambley TW, Cullinane CM, Lyons JG. Can metal complexes serve as hypoxia activated prodrugs? Investigations of a Co(III) complex of the MMP inhibitor marimastat. J Inorg Biochem 2003;96(1):128-128.
212. Vieites M, Noblia P, Torre MH, Cerecetto H, Lavaggi ML, Costa-Filho AJ, Azqueta A, de Cerain AL, Monge A, Parajon-Costa B, Gonzalez M, Gambino D. Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N-1,N-4-dioxide derivatives. J Inorg Biochem 2006; 100(8):1358-1367.
213. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J Med Chem 2006;49(25):7253-7269.
214. Vrudhula VM, MacMaster JF, Li ZG, Kerr DE, Senter PD. Reductively activated disulfide prodrugs of paclitaxel. Bioorg Med Chem Lett 2002;12(24):3591-3594.
215. Damen EWP, Nevalainen TJ, van den Bergh TJM, de Groot FMH, Scheeren HW. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg Med Chem 2002;10(1):71-77.
216. Jain M, Kwon CH. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation. J Med Chem 2003;46(25):5428-5436.